clinical trials cohort

Aliases

underpowered early-phase clinical trials

Related entities (4)

Mentioned in (29)

Papers in which this entity is mentioned.

• BRAIN-online: An online cognitive and behavioral screening tool for fetal alcohol spectrum disorders. (2026)
• Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort. (2026)
• The landscape of drug sensitivity and resistance in sarcoma. (2024)
• A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges. (2024)
• ENPP1 Immunobiology as a Therapeutic Target. (2023)
• Reducing Prenatal Alcohol Exposure and the Incidence of FASD: Is the Past Prologue? (2023)
• The effects of gestational choline supplementation on cerebellar Purkinje cell number in the sheep model of binge alcohol exposure during the first trimester-equivalent. (2022)
• Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. (2022)
• Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. (2021)
• Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. (2021)
• Polygenic risk scores: from research tools to clinical instruments. (2020)
• Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. (2019)
• Determining cell type abundance and expression from bulk tissues with digital cytometry. (2019)
• Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. (2019)
• Comprehensive Characterization of Cancer Driver Genes and Mutations. (2018)
• Tumor fraction in cell-free DNA as a biomarker in prostate cancer. (2018)
• Translating genome-wide association findings into new therapeutics for psychiatry. (2016)
• The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. (2016)
• Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. (2016)
• Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
• Integrative clinical genomics of advanced prostate cancer. (2015)
• Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. (2015)
• Is vitamin D deficiency a major global public health problem? (2014)
• Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. (2014)
• Do baseline P-values follow a uniform distribution in randomised trials? (2013)
• Within-subject template estimation for unbiased longitudinal image analysis. (2012)
• Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. (2012)
• Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. (2011)
• Why most published research findings are false. (2005)

Merged raw entities (2)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.